Antibodies to watch in 2024

References

• Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–35. doi: 10.1080/19420862.2018.1556465.
   PubMed Web of Science ®Google Scholar
• Thomas D, Chancellor D, Micklus A, LaFever S, Hay M, Chaudhuri S, Bowden R, Low AW. Clinical development success rates and contributing factors 2011–2020. Biotechnology Innovation Organization Report; 2021 Feb. [accessed 2023 Sept 12]. https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020.
   Google Scholar
• Thomas D, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M Clinical development success rates 2006-2015. Biotechnology Innovation Organization Report; 2016. [accessed 2023 Sept]. https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf.
   Google Scholar
• Hoy SM. Lecanemab: First Approval. Drugs. 2023;83(4):359–65. doi: 10.1007/s40265-023-01851-2.
   PubMed Web of Science ®Google Scholar
• Eisai. FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer’s disease; July 7, 2023, press release. [accessed 2023 Aug 15]. https://www.eisai.com/news/2023/news202349.html.
   Google Scholar
• U.S. Food and Drug Administration. RYSTIGGO® (rozanolixizumab-noli) injection, for subcutaneous use. [accessed 2023 Aug 16].
   Google Scholar
• Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Rozanolixizumab: first approval. Drugs. 2023;83(16):1569. doi: 10.1007/s40265-023-01960-y.
   PubMedGoogle Scholar
• Regeneron Pharmaceuticals, Inc. VEOPOZ™ (pozelimab-bbfg) receives FDA approval as the first treatment for children and adults with CHAPLE disease; 2023 Aug 18 press release. [accessed 2023 Oct 7]. https://investor.regeneron.com/news-releases/news-release-details/veopoztm-pozelimab-bbfg-receives-fda-approval-first-treatment.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Regeneron corporate presentation; 2023 Aug. [accessed 2023 Oct 27]. https://investor.regeneron.com/static-files/a73a7d9c-591d-43e4-905f-6851ac1ff04e.
   Google Scholar
• Keam SJ. Mirikizumab: first approval. Drugs. 2023;83(11):1045–52. doi: 10.1007/s40265-023-01909-1.
   PubMedGoogle Scholar
• Eli Lilly and Company. FDA approves Lilly’s Omvoh™ (mirikizumab-mrkz), a first-in-class treatment for adults with moderately to severely active ulcerative colitis; 2023 Oct 26 press release. [accessed 2023 Oct 27]. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class.
   Google Scholar
• Dubinsky MC, DB C, Hunter GT, Li X, Vermeire S, Hisamatsu T, SP T. Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. Crohn’s & Colitis 360. 2023;5(1). doi: 10.1093/crocol/otac044.
   Google Scholar
• Eli Lilly and Company. Lilly’s Mirikizumab helped patients with crohn’s disease achieve long-term remission in phase 3 trial; 2023 Oct 12 press release. [accessed 2023 Oct 27]. https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-helped-patients-crohns-disease-achieve-long.
   Google Scholar
• Janssen Pharmaceutical Companies of Johnson & Johnson. U.S. FDA approves TALVEY™ (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma; 2023 Aug 10 press release. [accessed 2023 Oct 27]. https://www.janssen.com/fda-approves-talveytm-talquetamab-tgvs-first-class-bispecific-therapy-treatment-patients-heavily.
   Google Scholar
• Janssen Pharmaceutical Companies of Johnson & Johnson. European Commission approves TALVEY® (talquetamab), Janssen’s novel bispecific therapy for the treatment of patients with relapsed and refractory multiple myeloma; 2023 Aug 22 press release. [accessed 2023 Oct 27]. https://www.janssen.com/european-commission-approves-talvey-talquetamab-janssens-novel-bispecific-therapy-treatment.
   Google Scholar
• Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen presents longer-term talquetamab follow-up data showing overall response rates of more than 70 percent in heavily pretreated patients with multiple myeloma; 2023 June 3 press release. [accessed 2023 Oct 27]. https://www.janssen.com/emea/sites/www_janssen_com_emea/files/talquetamab_monumental_and_trimm2_asco_2023_press_release_.pdf.
   Google Scholar
• Pfizer Inc. Pfizer’s ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma; 2023 Aug 14 press release. [accessed 2023 Oct 27]. https://investors.pfizer.com/Investors/News/news-details/2023/Pfizers-ELREXFIO-Receives-U.S.-FDA-Accelerated-Approval-for-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx.
   Google Scholar
• Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–2267. doi: 10.1038/s41591-023-02528-9.
   PubMed Web of Science ®Google Scholar
• Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs. 2013;5(6):962–73. doi: 10.4161/mabs.26233.
   PubMed Web of Science ®Google Scholar
• AbbVie. EPKINLY™ (epcoritamab-bysp) approved by U.S. FDA as the first and only bispecific antibody to treat adult patients with relapsed or refractory diffuse large B-Cell lymphoma (DLBCL); 2023 May 19 press release. [accessed 2023 Aug 19]. https://news.abbvie.com/news/press-releases/epkinly-epcoritamab-bysp-approved-by-us-fda-as-first-and-only-bispecific-antibody-to-treat-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl.htm
   Google Scholar
• U.S. Food and Drug Administration. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma; 2023 May 19. [accessed 2023 Aug 19]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell.
   Google Scholar
• Shirley M. Glofitamab: First Approval. Drugs. 2023;83(10):935–41. doi: 10.1007/s40265-023-01894-5.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. COLUMVI (glofitamab-gxbm) injection, for intravenous use. [accessed 2023 Sep 14]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf.
   Google Scholar
• European Medicines Agency. Columvi. [accessed 2023 Sep 14]. https://www.ema.europa.eu/en/medicines/human/EPAR/columvi
   Google Scholar
• U.S. Food and Drug Administration. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma; 2023 Mar 22. [accessed 2023 Aug 17]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel.
   Google Scholar
• Incyte. Incyte announces FDA approval of Zynyz™ (retifanlimab-dlwr) for the treatment of metastatic or recurrent locally advanced Merkel Cell Carcinoma (MCC); 2023 Mar 22 press release. [accessed 2023 Aug 17]. https://investor.incyte.com/news-releases/news-release-details/incyte-announces-fda-approval-zynyztm-retifanlimab-dlwr.
   Google Scholar
• Kang C. Retifanlimab: first approval. Drugs. 2023;83(8):731–37. doi: 10.1007/s40265-023-01884-7.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Concizumab: First Approval. Drugs. 2023;83(11):1053–59. doi: 10.1007/s40265-023-01912-6.
   PubMed Web of Science ®Google Scholar
• Biotech F. Novo Nordisk’s Hemlibra rival faces another approval setback as FDA raises dosing, manufacturing questions; 2023 May 4 post. [accessed 2023 Oct 27]. https://www.fiercebiotech.com/biotech/novo-nordisks-hemlibra-rival-faces-another-approval-setback-fda-raises-dosing-queries.
   Google Scholar
• Almirall SA Almirall receives European Commission approval of EBGLYSS® (lebrikizumab) for moderate-to-severe atopic dermatitis; 2023 Nov 17 press release. [accessed 2023 Nov 17]. https://www.almirall.com/newsroom/news/almirall-receives-european-commission-approval-of-ebglyss-lebrikizumab-for-moderate-to-severe-atopic-dermatitis.
   Google Scholar
• Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–1091. doi: 10.1056/NEJMoa2206714.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (adhere). JAMA Dermatology. 2023;159(2):182–191. doi: 10.1001/jamadermatol.2022.5534.
   PubMed Web of Science ®Google Scholar
• Innovent Biologics, Inc. The National Medical Products Administration approves anti-PCSK9 monoclonal antibody sintbilo®(tafolecimab injection) for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia. 2023 Aug 16 press release. [accessed 2023 Sept 23]. https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0816/2023081601083.pdf.
   Google Scholar
• Huo Y, Li Y, Zhang P, Deng H, Li H, An P, Xue F, Yu Z, Ma Q, Qi L, et al. Efficacy and safety of tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Circulation. 2022;146(Suppl_1):10111. doi:10.1161/circ.146.suppl_1.10111.
   Google Scholar
• Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(1):77. doi: 10.1186/s12916-023-02797-8.
   PubMed Web of Science ®Google Scholar
• Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, Li L, Wang S, Liu C, Zheng G, et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4). Asia: JACC; 2023. https://www.jacc.org/doi/10.1016/j.jacasi.2023.04.011
   Google Scholar
• CSPC Pharmaceutical Group Limited. Biologic license application for narlumosbart for injection (JMT103) approved by the NMPA; 2023 Sept 6 press release. [accessed 2023 Sept 23]. https://doc.irasia.com/listco/hk/cspc/announcement/a230906a.pdf.
   Google Scholar
• BioRay Pharmaceutical Co., Ltd. Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China; 2023 May 17 press release. [accessed 2023 Oct 27]. https://www.bioraypharm.com/index.php?m=content&a=index&classid=43&id=9.
   Google Scholar
• BioRay. 博锐生物淋巴瘤高峰论坛暨安瑞昔®泽贝妥单抗全国上市成功举行. [ Chinese]; 2023 July 2 press release. [accessed 2023 Sep 10]. https://www.bioraypharm.com/index.php?m=content&a=index&classid=40&id=100.
   Google Scholar
• Jiangsu Hengrui Medicine Co. Ltd. Hengrui Pharmaceutical’s PD-L1 inhibitor adebelimab (Arelili®) was approved, and the company has 12 innovative drugs on the market; 2023 Mar 7 press release. [accessed 2023 Sept 23]. https://www.hengrui.com/media/detail-309.html.
   Google Scholar
• Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–47. doi:10.1016/S1470-2045(22)00224-8.
   PubMed Web of Science ®Google Scholar
• BIOCAD. The Russian Ministry of Health has authorized the first Russian originator for the treatment of multiple sclerosis; 2023 Mar 31, press release. [accessed 2023 Aug 31]. https://biocadglobal.com/posts/the-russian-ministry-of-health-has-authorized-the-first-russian-originator-for-the-treatment-of-multiple-sclerosis.
   Google Scholar
• Eli Lilly and Company. U.S. Food and Drug Administration issues complete response letter for accelerated approval of donanemab; 2023 Jan 19 press release. [accessed 2023 Oct 27]. https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-issues-complete-response-0.
   Google Scholar
• Eli Lilly and Company. Results from Lilly’s landmark phase 3 trial of donanemab presented at Alzheimer’s Association Conference and published in JAMA. 2023 Jul 17 press release. [accessed 2023 Oct 27]. https://investor.lilly.com/news-releases/news-release-details/results-lillys-landmark-phase-3-trial-donanemab-presented.
   Google Scholar
• Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–527. doi: 10.1001/jama.2023.13239.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Lilly shares positive donanemab data in first active comparator study in early symptomatic Alzheimer’s disease; 2022 Nov 30 press release. [accessed 2023 Oct 27]. http://lilly.mediaroom.com/2022-11-30-Lilly-Shares-Positive-Donanemab-Data-in-First-Active-Comparator-Study-in-Early-Symptomatic-Alzheimers-Disease.
   Google Scholar
• Genentech. FDA accepts application for Genentech’s crovalimab for the treatment of PNH, a rare life-threatening blood condition; 2023 Sept 4 press release [accessed 2023 Sept 23]. https://www.gene.com/media/press-releases/15000/2023-09-04/fda-accepts-application-for-genentechs-cSept 2023.
   Google Scholar
• Liu H, Xia L, Weng J, Zhang F, He C, Gao S, Jia J, Chang AC, Lundberg P, Camelia S, et al. Results from the first phase 3 crovalimab (c5-inhibitor) study (commodore 3): efficacy and safety in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH). Presentation at: ASH Annual Meeting and Exposition; New Orleans, 2022 Dec 10-13; Abstract #293. doi:10.1182/blood-2022-162452.
   Google Scholar
• Scheinberg P, Cle D, Edwards J, Giai V, Hus M, Kim JS, Barrenetxea Lekue C, Nagy Z, Nur E, Panse J, et al. Phase III randomized, multicenter, open-label COMMODORE 1 trial: comparison of crovalimab vs eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH). Hemasphere. Aug 8, 2023;7(Suppl):e45540d8. doi:10.1097/01.HS9.0000967644.45540.d8.
   Google Scholar
• Röth A, He G, Brodsky A, Chai-Adisaksopha CC, Dumagay T, Demichelis R, Höglund M, Kelly R, Lee J-H, Nishimura J-I, et al. The PHASE III, randomized COMMODORE 2 trial: results from a multicenter study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients naive to complement inhibitors. Hemasphere. 2023;7(Suppl):e72750f1. doi:10.1097/01.HS9.0000967636.72750.f1.
   Google Scholar
• US Food and Drug Administration. FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19. April 4, 2023 press release. [accessed 2023 Oct 27]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-gohibic-vilobelimab-injection-treatment-covid-19.
   Google Scholar
• Lim EHT, Vlaar APJ, de Bruin S, Rückinger S, Thielert C, Habel M, Guo R, Burnett BP, Dickinson J, Brouwer MC, et al. PANAMO study group. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients. Intensive Care Med Exp. 2023;11(1):37. doi:10.1186/s40635-023-00520-8.
   PubMed Web of Science ®Google Scholar
• InflaRx N.V. InflaRx’s marketing authorization application (MAA) for vilobelimab for treatment of critically Ill COVID-19 patients under review by European Medicines Agency (EMA); 2023 Aug 30 press release. [accessed 2023 Oct 27]. https://www.inflarx.de/Home/Investors/Press-Releases/08-2023-InflaRx-s-Marketing-Authorization-Application–MAA–for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-under-Review-by-European-Medicines-Agency–EMA.html.
   Google Scholar
• Pfizer, Inc. Pfizer reports second-quarter 2023 results; 2023 Aug 1 press release. [accessed 2023 Sept 27]. https://s28.q4cdn.com/781576035/files/doc_financials/2023/q2/Q2-2023-PFE-Earnings-Release.pdf.
   Google Scholar
• European Medicines Agency. Applications for new human medicines under evaluation by the CHMP: November 2023; Published 2023 Nov 7 data extracted 2023 Oct 30. [accessed 2023 Nov 7]. https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation.
   Google Scholar
• Pfizer, Inc. Pfizer announces positive marstacimab results from pivotal phase 3 hemophilia a and B trial; 2023 May 30 press release. [accessed 2023 Sept 27]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-marstacimab-results-pivotal-phase.
   Google Scholar
• CSL. CSL Limited 2023 Full Year Results; 2023 Aug 15. [accessed 2023 Oct 20]. https://investors.csl.com/pdf/5180b107-7849-4ad4-aeaf-8092e62b4bb6/CSL-Results-Presentation.pdf.
   Google Scholar
• Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10382):1079–1090. doi:10.1016/S0140-6736(23)00350-1.
   PubMed Web of Science ®Google Scholar
• Omeros Corporation. Omeros announces online publication in advance of ASH annual meeting detailing narsoplimab treatment under compassionate use of 15 patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy; 2023 Nov 3 press release. [accessed 2023 Nov 4]. https://investor.omeros.com/news-releases/news-release-details/omeros-announces-online-publication-advance-ash-annual-meeting.
   Google Scholar
• Castelli M, Mico’ MC, Grassi A, Algarotti A, Finazzi MC, Rambaldi B, Cristian Meli C, Rizzuto G, Pavoni C, Vendemini F, et al. Clinical safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience. 65th Annual Meeting of the American Society of Hematology, December 9-12, 2023, San Diego. https://ash.confex.com/ash/2023/webprogram/Paper180917.html.
   Google Scholar
• Checkpoint Therapeutics, Inc. Checkpoint therapeutics reports second quarter 2023 financial results and recent corporate highlights; 2023 Aug 14 press release. [accessed 2023 Oct 27]. https://ir.checkpointtx.com/news-events/press-releases/detail/104/checkpoint-therapeutics-reports-second-quarter-2023.
   Google Scholar
• Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023;11(10):e007637. doi: 10.1136/jitc-2023-007637.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Astellas announces U.S. FDA grants priority review for zolbetuximab biologics license application; 2023 July 6 press release. [accessed 2023 Oct 27]. https://www.astellas.com/en/news/27946.
   Google Scholar
• Astellas Pharma Inc. European Medicines Agency accepts Astellas’ marketing authorization application for zolbetuximab; 2023 July 13 press release. [accessed 2023 Oct 27]. https://www.astellas.com/en/news/28146.
   Google Scholar
• Astellas Pharma Inc. China’s National Medical Products Administration accepts Astellas’ biologics license application for zolbetuximab; 2023 July 31 press release. [accessed 2023 Oct 27]. https://www.astellas.com/en/news/28211.
   Google Scholar
• Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655–1668. doi:10.1016/S0140-6736(23)00620-7.
   PubMed Web of Science ®Google Scholar
• Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133–2141. doi: 10.1038/s41591-023-02465-7.
   PubMed Web of Science ®Google Scholar
• Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O’Brien SM, Chávez JC, Duell J, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327–e39. doi:10.1016/S2352-3026(22)00072-2.
   PubMed Web of Science ®Google Scholar
• Kim W-S, Kim TM, Cho S-G, Jarque I, Iskierka-Jażdżewska E, Poon ML, Prince HM, Oh SY, Lim F, Carpio C, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2. Blood. 2022;140(Supplement 1):1070–71. doi: 10.1182/blood-2022-158406.
   Google Scholar
• Byondis BV. U.S. Food and Drug Administration issues complete response letter for Byondis’ [Vic-]Trastuzumab Duocarmazine; 2023 May 15 press release. [ accessed 2023 Oct 23]. https://www.byondis.com/media/press-releases/us-food-and-drug-administration-issues-complete-response-letter-for-vic-trastuzumab-duocarmazine.
   Google Scholar
• Byondis BV Withdrawal of Jivadco (trastuzumab duocarmazine), 80 mg, powder for concentrate for solution for infusion - EMEA/H/C/005654; 2023 Sept 12 letter. [accessed 2023 Oct 18]. https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-jivadco_en.pdf.
   Google Scholar
• Byondis BV Byondis announces positive topline results of pivotal phase III TULIP® study in patients with her2-positive unresectable locally advanced or metastatic breast cancer; 2021 June 8 press release. [accessed 2023 Oct 23]. https://www.byondis.com/media/press-releases/byondis-announces-positive-topline-results-of-pivotal-phase-iii-tulip-study.
   Google Scholar
• Wong KL, Li Z, Ma F, Wang D, Song N, Chong CH, Luk KK, Leung SO. SM03, an anti-CD22 antibody, Converts Cis-to-Trans Ligand Binding of CD22 against α2,6-linked sialic acid glycans and immunomodulates systemic autoimmune diseases. J Immunol. 2022;208(12):2726–2737. doi: 10.4049/jimmunol.2100820.
   PubMed Web of Science ®Google Scholar
• SinoMab BioScience Limited. BLA accepted by the NMPA for SM03 (suciraslimab) in the treatment of rheumatoid arthritis; 2023 Sept 5 press release. [accessed 2023 Oct 9]. https://manager.wisdomir.com/files/517/2023/0905/20230905121501_30698040_en.pdf.
   Google Scholar
• SinoMab BioScience Limited. SinoMab announces that phase III clinical trial of its flagship product SM03 (suciraslimab) achieved the primary endpoint for rheumatoid arthritis; 2023 Apr 26 press release. [accessed 2023 Oct 9]. https://www.sinomab.com/wp-content/uploads/2023/04/Press-Release-SinoMab-3681.HK-Announces-that-Phase-III-Clinical-Trial-of-its-Flagship-Product-SM03-Suciraslimab-Achieved-the-Primary-Endpoint-for-Rheumatoid-Arthritis.pdf.
   Google Scholar
• Harbour BioMed. Harbour BioMed announces positive topline results from phase III trial of batoclimab for treatment of generalized myasthenia gravis; 2023 Mar 6 press release. [accessed 2023 Sep 2025]. https://www.prnewswire.com/news-releases/harbour-biomed-announces-positive-topline-results-from-phase-iii-trial-of-batoclimab-for-treatment-of-generalized-myasthenia-gravis-301763029.html.
   Google Scholar
• Akeso Inc. Akeso announced NDA acceptance of IL-12/lL-23 monoclonal antibody ebdarokimab for moderate-to-severe plaque psoriasis by China NMPA; 2023 Aug 24 press release. [accessed 2023 Oct 7]. https://www.akesobio.com/en/media/akeso-news/230824/.
   Google Scholar
• Medicine Cube. The first domestically produced one! Zhixiang Jintai’s anti-IL-17A monoclonal antibody has been submitted for marketing; 2023 Mar 25 post. [accessed 2023 Oct 17]. https://www.pharmcube.com/index/news/article/13097.
   Google Scholar
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. R&D pipeline by Mar. 31, 2023. [accessed 2023 Oct 8]. https://www.hengrui.com/en/pipeline.html.
   Google Scholar
• Xu J, Yan K, Han L, Zhang Z, Li F, Bi X, Li Y, Zhang L, Wang X, Li L, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. European Academy Of Dermatology And Venereology Congress, Abstract, 11–14 October, 2023, Berlin. https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eadv/abstracts_congress2023/32842.pdf
   Google Scholar
• Akeso Inc. NMPA accepted Akeso’s ebronucimab (PCSK9) marketing application in two indications. 2023 June 2 press release. [accessed 2023 Sept 25]. https://www.akesobio.com/en/media/akeso-news/230602/.
   Google Scholar
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. 2023 ESC annual meeting: a phase III study of Hengrui Pharmaceuticals’ innovative lipid-lowering drug recarcizumab was presented as an oral report; 2023 Aug 29 press release. [accessed 2023 Oct 8]. https://www.hengrui.com/media/detail-393.html.
   Google Scholar
• Junshi Biosciences. Junshi Biosciences announces ongericimab (anti-PCSK9 mAb) met primary endpoints in two phase 3 clinical studies; 2023 Feb 28 press release. [accessed 2023 Sept 25]. https://www.biospace.com/article/releases/junshi-biosciences-announces-ongericimab-anti-pcsk9-mab-met-primary-endpoints-in-two-phase-3-clinical-studies/.
   Google Scholar
• Sichuan Kelun-Biotech Biopharmaceutical Co Ltd. 2023 Interim Report. [accessed 2023 Oct 16]. https://ir-upload.realxen.net/iis/6990/uploads/iis/2023/10901518-0.PDF.
   Google Scholar
• CSPC Pharmaceuticals. NMPA acceptance of application for marketing approval of enlonstobart for injection; 2023 Mar 13 press release. [accessed 2023 Oct 16]. https://en.e-cspc.com/news/nmpa-acceptance-of-application-for-marketing-approval-of-enlonstobart-for-injection.html.
   Google Scholar
• Medicine Cube. Qilu Pharmaceutical’s PD-1 antibody “ipalolizumab” applies for marketing; 2023 Sept 17 post. [accessed 2023 Oct 16]. https://bydrug.pharmcube.com/news/detail/bc171f6b537a767dfbc996adbdfc5c85.
   Google Scholar
• Liu J, Fang C, Zhou Q, He L, Yu J, Li Y, Feng M, Pan M, Zhao L, Tang D, et al. A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer. Ann Oncol. 2022;33(suppl_9):S1503–S14. doi:10.1016/annonc/annonc1126.
   Google Scholar
• Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, et al. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol. 2023;16(1):50. doi: 10.1186/s13045-023-01445-1.
   PubMed Web of Science ®Google Scholar
• Akeso B. Akeso’s ivonescimab (PD-1/VEGF bispecific antibody, AK112) granted breakthrough therapy designation for I-O resistance NSCLC patients in China; 2022 Nov 13 press release. [accessed 2023 Oct 7]. https://prn.to/3tx62MK.
   Google Scholar
• Akeso Inc. Akeso announced that ivonescimab granted priority review of NDA by China NMPA; 2023 Aug 25 press release. [accessed 2023 Oct 7]. https://www.prnewswire.com/news-releases/akeso-announced-that-ivonescimab-granted-priority-review-of-nda-by-china-nmpa-301910028.html
   Google Scholar
• Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, et al. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023;62:102106. doi:10.1016/j.eclinm.2023.102106. 102106.
   PubMedGoogle Scholar
• Sorrento Therapeutics, Inc. Corporate presentation; 2023 Jan. [accessed 2023 Sept 25]. https://investors.sorrentotherapeutics.com/static-files/ded13448-aa64-4405-a2d9-de644cfe9dfc.
   Google Scholar
• An J, Tang J, Li BX, Xiong H, Qiu H, Luo L, Wang L, Wang D, Zhou Q, Xu Q, et al. Efficacy and safety of the anti-PD-L1 mAb socazolimab for recurrent or metastatic cervical cancer: a phase I dose-escalation and expansion study. Clin Cancer Res. 2022;28(23):5098–106. doi:10.1158/1078-0432.CCR-22-1280.
   PubMed Web of Science ®Google Scholar
• Lu S, Chen Z, Cui J, Guo R, Li Z, Xiaoyi B, Day X. Efficacy and safety of anti–programmed death-ligand 1 monoclonal antibody socazolimab with carboplatin and Etoposide for extensive-stage SCLC: results from the phase 1b clinical trial. JTO Clin Res Reports. 2023;4(4):4. doi: 10.1016/j.jtocrr.2023.100478.
   Google Scholar
• Sino Pharmaceutical Limited. Application for marketing of category 1 innovative drug TQB2450 injection in combination with anlotinib hydrochloride capsules for the indication of first-line treatment of small cell lung cancer accepted; 2023 Jan 13 press release. [accessed 2023 Oct 7]. https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0113/2023011300357.pdf.
   Google Scholar
• Sichuan Kelun Pharmaceutical Co., Ltd. Announcement on the acceptance of the marketing application for the new PD-L1 drug tetelimab injection by NMPA [Chinese]; 2021 Nov 19 press release. [accessed 2023 Sept 25]. http://static.cninfo.com.cn/finalpage/2021-11-20/1211637118.PDF.
   Google Scholar
• Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, Qiu S, Pan S, Zheng Y, Cai J, et al. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg Health West Pac. 2022;31:100617. doi:10.1016/j.lanwpc.2022.100617. PMID: 36879786.
   PubMedGoogle Scholar
• Syndax Pharmaceuticals, Inc. SNDX third quarter 2023 results; 2023 Nov 2 presentation. [accessed 2023 Nov 4]. https://ir.syndax.com/static-files/b92ab47e-8e26-46bf-af5b-d5f135f54f10.
   Google Scholar
• Syndax Pharmaceuticals, Inc. Corporate presentation; 2023 Aug. [accessed 2023 Oct 16]. https://ir.syndax.com/static-files/1c3a5493-5046-4d16-a9da-0bfda68ec4d9.
   Google Scholar
• RQ Biotechnology Limited. Innovative antibody discovered by RQ BIO enters clinic as part of antibody combination within 12 months of discovery; 2022 Dec 21 press release. [accessed 2023 Sept 25]. https://www.rqbiotechnology.com/media/innovative-antibody-discovered-by-rq-bio-enters-clinic-as-part-of-antibody-combination-within-12-months-of-discovery.
   Google Scholar
• AstraZeneca. Clinical trials appendix, 9M and Q3 2023 results update; 2023 Nov 9. [accessed 2023 Nov 10]. https://www.astrazeneca.com/content/dam/az/PDF/2023/q3/9M_and_Q3_2023_results_clinical_trials_appendix.pdf.
   Google Scholar
• SERB Pharmaceuticals. SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent; 2023 May 11 press release. [accessed 2023 Oct 16]. https://serb.com/news/serb-pharmaceuticals-and-sfj-pharmaceuticals-announce-a-u-s-partnership-for-bentracimab-a-ticagrelor-reversal-agent/.
   Google Scholar
• Bhatt DL, Pollack CV Jr., Mazer CD, Angiolillo DJ, Steg G, James SK, Weitz JI, Ramnath R, Arnold SE, Mays MC, et al. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evid. 2022;1(3). doi: 10.1056/EVIDoa2100047.
   Google Scholar
• Keymed Biosciences. 2022 Annual results and latest updates; 2023 Mar presentation. [accessed 2023 Sept 25]. https://en.keymedbio.com/uploadfile/2023/0317/20230317080809187.pdf
   Google Scholar
• Zhao Y, Zhang J, Yang B, Li J, Ding Y, Wu L, Zhang L, Wang J, Zhu X, Zhang F, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial. Chin Med J (Engl). 2023. doi:10.1097/CM9.0000000000002747.
   Google Scholar
• Zhang L, Ding Y, Wang Q, Pan W, Wei Z, Smith PA, Yang X. Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023;13:12411. doi: 10.1038/s41598-023-39311-2.
   PubMed Web of Science ®Google Scholar
• Connect Biopharma Holdings Limited. Connect biopharma and simcere announce exclusive licensing and collaboration agreement in Greater China; 2023 Nov 21 press release. [accessed 2023 Nov 21]. https://investors.connectbiopharm.com/news-releases/news-release-details/connect-biopharma-and-simcere-announce-exclusive-licensing-and.
   Google Scholar
• Suzhou Connect Biopharmaceuticals, Ltd. Connect biopharma, top line results: CBP-201 pivotal trial in China (CN002); 2022 Oct. [accessed 2023 Sept 25]. https://investors.connectbiopharm.com/static-files/e98617f2-b84a-4aa9-9123-8cb766cd17ad.
   Google Scholar
• Connect Biopharma Holdings Limited. Connect biopharma announces positive long-term data from the China pivotal trial of rademikibart in patients with moderate-to-severe atopic dermatitis; 2023 Nov 21 press release. [accessed 2023 Nov 21]. https://investors.connectbiopharm.com/news-releases/news-release-details/connect-biopharma-announces-positive-long-term-data-china.
   Google Scholar
• GSK. Third quarter 2023 results; 2023 Nov 1 presentation. [accessed 2023 Nov 4]. https://www.gsk.com/media/10668/q3-2023-results-slides.pdf.
   Google Scholar
• AnaptysBio, Inc. Anaptys announces positive top-line phase 3 clinical trial results of imsidolimab (IL-36R) in generalized pustular psoriasis (GPP); 2023 Oct 9 press release. [accessed 2023 Oct 25]. https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial.
   Google Scholar
• Kurnellas M, Mitra A, Schwabe T, Paul R, Arrant AE, Roberson ED, Ward M, Yeh F, Long H, Rosenthal A. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023;21(1):387. doi: 10.1186/s12967-023-04251-y.
   PubMed Web of Science ®Google Scholar
• Alector, Inc. Alector announces achievement of target enrollment in the pivotal INFRONT-3 phase 3 clinical trial of latozinemab in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN); 2023 Oct 27 press release. [accessed 2023 Nov 4]. https://investors.alector.com/news-releases/news-release-details/alector-announces-achievement-target-enrollment-pivotal-infront.
   Google Scholar
• Scholar Rock. Deep insights advancing impactful medicines; 2023 Oct corporate presentation. [accessed 2023Oct 25]. https://investors.scholarrock.com/static-files/3645e0f2-3012-4c8f-8b2f-6e1c57bd68fe.
   Google Scholar
• Regeneron. Regeneron corporate presentation; 2023 Nov. [accessed 2023 Nov 4]. https://investor.regeneron.com/static-files/27bf1467-a410-414b-9bec-916fa90e7748.
   Google Scholar
• Regeneron. Updated linvoseltamab (BCMAxCD3) data from pivotal trial demonstrates early, deep and durable responses in patients with heavily pre-treated multiple myeloma; 2023 May 25 press release. [accessed 2023 Oct 20]. https://investor.regeneron.com/news-releases/news-release-details/updated-linvoseltamab-bcmaxcd3-data-pivotal-trial-demonstrates.
   Google Scholar
• Weisel K, Hungria V, Quach H, Yoon S-S, Rodríguez-Otero P, Kroog G, Sinha A, Boyapati A, Lyon C, Lorenc KR, et al. PB2133: trial in progress: LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPD) in relapsed/refractory multiple myeloma (RRMM). Hemasphere. 2023;7(Suppl):e465366a. doi:10.1097/01.HS9.0000975296.46536.6a.
   Google Scholar
• Actinium Pharmaceuticals, Inc. Investor presentation: targeted radiotherapies for patients with unmet needs; 2023 Sept. [accessed 2023 Oct 20]. https://d1io3yog0oux5.cloudfront.net/_e867432f4d7e6dd09397644109efb94f/actiniumpharma/db/206/1137/pdf/Actinium+Investor+Presentation±+September+2023+FINAL.pdf.
   Google Scholar
• Actinium Pharmaceuticals, Inc. Iomab-B SIERRA trial: Phase 3 results; 2023 Feb 18. [accessed 2023 Oct 20]. https://d1io3yog0oux5.cloudfront.net/_e867432f4d7e6dd09397644109efb94f/actiniumpharma/db/206/1110/pdf/Actinium_SIERRA_Data_Webcast_vFINAL_02.18.2023.pptx+for+webinar.pdf.
   Google Scholar
• Roche. YTD September 2023 performance. [accessed 2023 Oct 20]. https://assets.roche.com/f/176343/x/84b57800eb/irp231019.pdf.
   Google Scholar
• Roche. HY 2023 results; 2023 July 27. [ accessed 2023 Sept 25]. https://assets.cwp.roche.com/f/176343/x/418a8c95c6/irp230727.pdf.
   Google Scholar
• Genentech provides update on phase III skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer; 2023 Aug. [accessed 2023Sept 25] https://www.gene.com/media/press-releases/14998/2023-08-22/genentech-provides-update-on-phase-iii-s.
   Google Scholar
• Sanofi. Q3 2023 results; 2023 Oct 27. [accessed 2023 Nov 4]. https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2023/2023-q3-2023-results/q3-2023-presentation-en.pdf.
   Google Scholar
• Daiichi Sankyo. Daiichi Sankyo and Merck & Co., Inc., Rahway, N.J., USA announce global development and commercialization collaboration for three Daiichi Sankyo DXd ADCs; 2023 Oct 20 press release. [accessed 2023 Oct 20]. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202310/20231020_E.pdf.
   Google Scholar
• Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;JCO2301476. doi:10.1200/JCO.23.01476.
   Google Scholar
• Daiichi Sankyo Co., Ltd. Datopotamab deruxtecan significantly extended progression-free survival versus chemotherapy in patients with HR positive, HER2 low or negative breast cancer in TROPION-Breast01 phase 3 trial; 2023 Oct 23 press release. [accessed 2023 Oct 20]. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202310/20231023_E2.pdf.
   Google Scholar
• Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, et al. TROPION-Breast01: datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Future Oncol. 2023. doi:10.2217/fon-2023-0188.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Co., Ltd. Datopotamab deruxtecan improved progression-free survival versus chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 phase 3 trial; 2023 Oct 23 press release. [accessed 2023 Oct 24]. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202310/20231023_E3.pdf.
   Google Scholar
• Li H, Zhang X, Xu Z, Li L, Liu W, Dai Z, Zhao Z, Xiao L, Li H, Hu C. Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antib Ther. 2021;4(3):175–84. doi:10.1093/abt/tbab017.
   PubMedGoogle Scholar
• Biopharma L. 2023 Interim Report. September 2023 [accessed 2023 Oct 24]. https://en.lepubiopharma.com/upload/listedco/listconews/sehk/2023/0922/2023092200478.pdf.
   Google Scholar
• Agenus, Inc. Agenus reports third quarter 2023 results; 2023 Nov 7 press release. [accessed 2023 Nov 10] https://investor.agenusbio.com/news/news-details/2023/Agenus-Reports-Third-Quarter-2023-Results/default.aspx.
   Google Scholar
• Bullock AJ, Fakih MG, Gordon MS, Tsimberidou A, El-Khoueiry A, Wilky B, Pimentel A, Margolin K, Mahadevan D, Balmanoukian A, et al. Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Annals Of Oncology. 2023;34(suppl 1):S178–S79. doi:10.1016/j.annonc.2023.04.014.
   Google Scholar
• Philogen. Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in recurrence-free survival for patients with locally advanced fully resectable melanoma; 2023 Oct 16 press release. [accessed 2023 Oct 24]. https://www.philogen.com/philogen/wp-content/uploads/2023/10/Press_release_PIVOTAL.pdf.
   Google Scholar
• Merus N.V. Merus’ Zeno interim data continues to demonstrate robust and durable responses in NRG1+ cancer; 2023 Oct 23 press release. [accessed 2023 Oct 24]. https://ir.merus.nl/news-releases/news-release-details/merus-zeno-interim-data-continues-demonstrate-robust-and-durable.
   Google Scholar
• Schram AM, Goto K, Kim D-W, Hollebecque A, Rha SY, Nishino K, Duruisseaux M, Umemoto K, Park JO, Leighl N, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Oral Presentation At The European Society For Medical Oncology (ESMO) Congress; 2023 Oct 20-24, Madrid, Spain. https://merus.nl/wp-content/uploads/2023/10/ESMO%202023%20NSCLC%20Mini%20Oral%20Pres%20(MOZ-75963)_vFinal_19Oct2023.pdf.
   Google Scholar
• Schram AM, Macarulla T, Cleary JM, Neuzillet C, Arnold D, Reiss KA, Bekaii-Saab T, Rodon J, Goto K, Rha SY, et al. Durable efficacy of zenocutuzumab, a HER2 × HER3 bispecific antibody, in advanced NRG1 fusion–positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC). Poster presented at the European Society for Medical Oncology (ESMO) Congress 2023, 20-24 Oct 2023, Madrid, Spain. https://merus.nl/wp-content/uploads/2023/10/ESMO2023NRG1+PDAC.pdf.
   Google Scholar
• Alphamab Oncology. 2023 interim results presentation. [accessed 2023 Oct 24]. https://www.alphamabonc.com/en/uploads/2023/08/169286574293454.pdf.
   Google Scholar
• Alphamab Oncology. Updates in relation to a phase III clinical trial of KN046 for the treatment of advanced SQ NSCLC; 2023 May 19 press release. [accessed 2023 Oct 24]. https://www.alphamabonc.com/en/uploads/2023/05/168445306222985.pdf.
   Google Scholar
• I-Mab. I-Mab provides mid-year 2023 financial results, business and corporate updates; 2023 Aug 17 press release. [accessed 2023 Sept 25]. https://ir.i-mabbiopharma.com/news-releases/news-release-details/i-mab-provides-mid-year-2023-financial-results-business-and.
   Google Scholar
• Human Immunology Biosciences. HI-Bio receives FDA orphan drug designation for felzartamab for the treatment of membranous nephropathy; 2023 May 25 press release. [accessed 2023 Sept 25]. https://hibio.com/news/hi-bio-receives-fda-orphan-drug-designation-for-felzartamab-for-the-treatment-of-membranous-nephropathy.
   Google Scholar
• Novartis Pharmaceutical Corporation. Q3 2023 results investor presentation; 2023 Oct. [accessed 2023 Nov 4]. https://www.novartis.com/sites/novartiscom/files/q3-2023-investor-presentation.pdf.
   Google Scholar
• Zeidan AM, Ando K, Rauzy O, Turgut M, Wang M-C, Cairoli R, Hou H-A, Kwong Y-L, Sangerman MA, Meers S, et al. Primary results of stimulus-MDS1: a randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with sabatolimab added to hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS). Blood. 2022;140(Supplement 1):2063–65. doi:10.1182/blood-2022-158612.
   PubMedGoogle Scholar
• Crescioli S, Reichert JM. Trends in the commercial development of antibody therapeutics: the early stage clinical pipeline; 2023 Oct 24 online presentation. [accessed 2023 Nov 11]. https://www.youtu.be/Z0SvGPbpk7s.
   Google Scholar